Atherosclerosis Drugs: Nitrates and Nitric Oxide Signaling

Cell-Cell Signaling: quick recap

• Autocrine signaling: the cell activates itself by releasing a signaling molecule that binds its own receptor.

• Paracrine signaling: localized signaling; acts in a local area because the signaling molecule is often unstable and does not travel far.

• Endocrine signaling: hormones travel through blood to distant targets; signals are distal from release site.

• Nervous signaling: neurons release neurotransmitters to control tissues; fast, targeted communication.

Diseases and drug industry context

• Major diseases and death: heart disease and cancer are leading causes; heart disease is a top killer for both males and females; stroke is a top five killer.

• Why chronic diseases matter for drugs: drug companies favor chronic diseases because patients may need long-term treatment (years or decades), increasing drug use and revenue.

• Contrast with acute diseases: infections (e.g., bacterial infections treated by antibiotics) are less lucrative due to short treatment duration.

• Age-related disease progression: early life deaths are often non-natural (accidents, homicide, birth defects); after decades, cancer and heart disease become prominent chronic risks.

• Atherosclerosis as a major cause of death: many heart disease cases stem from atherosclerosis; it can also cause stroke due to arterial blockage or rupture.

• Sex differences in Alzheimer’s risk versus treatment: Alzheimer's higher in women; less effective drugs discussed.

Atherosclerosis: pathophysiology (arteries focus)

• Arteries vs veins: arteries deliver oxygenated blood; veins carry deoxygenated blood.

• LDL transport and fatty streak formation: LDL cholesterol gets stuck in arterial walls due to sticky lipids, forming fatty deposits (fatty streaks).

• Oxidation and injury: embedded lipids can be oxidized; oxidized LDL can be toxic and promote injury and inflammation.

• Aging and genetic factors: aging increases LDL deposition; genetic disorders increasing LDL accelerate fatty streak formation.

• Inflammation and immune response: injury attracts immune cells; inflammation can worsen injury and plaque.

• Plaque growth and narrowing: plaques narrow arteries; platelet aggregation can form a thrombus (scab) that worsens blockage.

• Thrombosis and clinical consequences: a thrombus can dislodge and occlude coronary arteries, causing myocardial infarction (heart attack); cerebral arteries occlusion causes stroke; aneurysm rupture can also cause stroke.

• Ischemia and angina: reduced oxygen delivery leads to tissue injury and chest pain (angina pectoris).

• Major arteries of concern: coronary arteries supplying the heart are particularly critical; blockage here is a major cause of heart attack.

• Lifespan context: arteries carry fats for decades; blockages accumulate with age; typical lifespan around ~
  $78\text{ years}$ in discussion; long-term fatty deposits contribute to chronic disease progression.

Nitrates and nitroglycerin: historical context and clinical use

• Nitrates treat angina (chest pain) by dilating vessels and reducing heart work.

• Nitroglycerin: an old, nitrogen-based nitrate; tiny doses (e.g., $0.6\ \text{mg}$) are used; sublingual administration provides rapid absorption.

• Surprising origin story: nitroglycerin originated as an explosive used in dynamite and bombs; discovered to cause vasodilation and lower blood pressure in workers; accidental discovery led to medicinal use.

• Nobel connection: nitroglycerin and its stabilization by Nobel predecessor sparked later Nobel Prizes recognizing signaling mechanisms; Nobel’s legacy links to stabilization of nitroglycerin and discovery of NO signaling.

• Sublingual delivery: under the tongue absorption is fast due to rich blood vessels; preferred for chest-pain relief due to rapid onset versus oral ingestion.

How nitrates work: from explosive to NO first messenger

• Core question: how does nitroglycerin cause vasodilation? Early mystery solved decades later.

• Mechanistic cascade begins with conversion to nitric oxide (NO): nitroglycerin in blood is converted to NO via enzymatic and other breakdown pathways.

• NO as first messenger: a localized, short-lived signaling molecule (paracrine) that can diffuse across membranes but does not travel far; NO signaling is limited to a local vascular region.

• NO triggers a signaling cascade in smooth muscle to cause vasodilation, reducing cardiac workload and improving oxygen delivery.

• NO signaling is an example of a paracrine pathway rather than endocrine (local action).

Artery signaling architecture: endothelial and smooth muscle cells

• Endothelial cells line the lumen and contact blood; they are a key source of NO in response to stimuli.

• Smooth muscle cells surround the endothelium and control vessel constriction/dilation.

• Communication axis: endothelial NO diffuses to adjacent smooth muscle cells to regulate tone.

• Endothelial and smooth muscle interactions involve calcium-dependent enzymes and signaling proteins.

NO signaling pathway: endothelial NO synthase and guanylyl cyclase

• Initiation: endothelial cells experience calcium rise and activate nitric oxide synthase (NOS) via calmodulin binding; NOS converts L-Arginine to NO and L-Citrulline:
  $\text{L-Arginine} \rightarrow NO + \text{L-Citrulline}$

• Activation trigger: NOS is calcium/calmodulin dependent; calcium elevations in endothelial cells activate NOS.

• NO diffusion: NO diffuses across membranes into smooth muscle cells where it encounters soluble guanylyl cyclase (sGC).

• NO-sGC interaction: NO binds the iron-centered heme of soluble guanylyl cyclase, activating the enzyme.

• cGMP production: activated sGC converts GTP to cyclic GMP (cGMP):
  $\mathrm{GTP} \rightarrow \mathrm{cGMP}$

• cGMP role: second messenger that binds and activates protein kinase G (PKG) in smooth muscle.

• PKG effects: PKG phosphorylation events decrease intracellular Ca2+ and promote relaxation of smooth muscle, causing vasodilation.

• Important concept: NO is a first messenger; cGMP is a second messenger that propagates the signal inside the cell.

The downstream signaling: PKG, calcium, and vasodilation

• NO diffusion leads to sGC activation and cGMP production in smooth muscle cells.

• cGMP activates PKG (cGMP-dependent protein kinase). This triggers a cascade that reduces intracellular Ca2+.

• Reduced Ca2+ in smooth muscle promotes relaxation and vasodilation, improving blood flow and decreasing myocardial oxygen demand.

• Net effect of nitrates: dilation of coronary arteries and veins, improved blood flow, reduced heart workload, and relief of angina.

• Important nuance: nitrates primarily affect downstream effectors in smooth muscle cells, not upstream endothelial cells.

The signaling cascade in detail: a domino-like sequence

• Domino analogy: each step must occur for the next to happen; a failure at any step disrupts the signaling.

• Pathway steps (summary):
  1) NO is produced by endothelial NOS (eNOS) in response to Ca2+/calmodulin.
  2) NO diffuses to smooth muscle and activates soluble guanylyl cyclase (sGC).
  3) sGC converts $\mathrm{GTP} \rightarrow \mathrm{cGMP}$ in smooth muscle.
  4) $\mathrm{cGMP}$ activates PKG.
  5) PKG phosphorylates targets that lower cytosolic Ca2+ and promote relaxation.

• NOS role: endothelial NOS synthesizes NO from L-Arginine; NOS activation is Ca2+/calmodulin dependent.

• Calcium role: Ca2+ in endothelial cells triggers NOS activation; in smooth muscle, lower Ca2+ reduces contraction.

• NO as a short-lived signal: NO degrades rapidly and has limited diffusion distance (roughly a few cells; approximate estimate given as 3–4 cells).

• NO chemical properties: NO is a hydrophobic, gaseous free radical; it crosses membranes but is short-lived and reactive.

Receptor and enzyme targets: receptor guanylyl cyclase and GPCRs

• Receptors as drug targets: many drugs target receptors due to specific ligand binding pockets.

• GPCRs discussed: muscarinic M3 receptor is a GPCR activated by acetylcholine; downstream signaling can connect to NO pathways via calcium signaling.

• G-protein signaling outline (brief): ligand binds GPCR → G protein activation → phospholipase C (PLC) activation → generation of inositol trisphosphate (IP3) → Ca2+ release from the endoplasmic reticulum (ER).

• IP3 pathway role: Ca2+ release from ER contributes to various downstream steps; in the NO pathway, calcium can activate NOS in endothelial cells.

• Receptor guanylyl cyclase (rGC): a receptor/enzyme that binds NO (in the cytoplasm as soluble guanylyl cyclase) to synthesize $\mathrm{cGMP}$ from $\mathrm{GTP}$; distinct from membrane-bound rGCs that are activated by peptide ligands.

• NO-sGC-cGMP-PKG axis as a canonical direct drug target: nitrates act upstream by delivering NO; downstream signaling targets cGMP and PKG.

Turning off the signal: the off-switch concept in signaling

• Why turning off signals matters: prolonged vasodilation can cause dangerous hypotension; signaling must be tightly regulated.

• NO degradation: NO is reactive and short-lived; it is scavenged by hemoglobin, metals, and reactive species; this rapidly terminates NO signaling.

• Second messenger termination: cGMP levels are controlled by phosphodiesterases (PDEs) that degrade cGMP to GMP:
  $\mathrm{cGMP} \xrightarrow{\text{PDE}} \mathrm{GMP}$

• Off-switch concept in drug design: PDE inhibitors can prolong signaling by preventing cGMP breakdown; conversely, targeting PDEs can dampen signaling.

• Upstream vs downstream: nitrates affect downstream signaling events; upstream components (e.g., NO production in endothelium via NOS) are not directly affected by nitrates.

Drug design perspectives and exam-style thinking

• Receptors and enzymes are primary drug targets due to specificity.

• GPCRs (e.g., M3 receptor) and receptor guanylyl cyclase are key druggable families in this NO signaling context.

• Downstream targets vs upstream targets:

  • Upstream targets: NOS activation, NO production, Ca2+ signaling leading to NOS activation.

  • Downstream targets: sGC activation, cGMP production, PKG activation, Ca2+ handling in smooth muscle.

• If you block any step in the domino chain, the downstream vasodilatory response is reduced or abolished.

• If you enhance or prolong the signal (e.g., PDE inhibition), the vascular response is prolonged; this is a common strategy in cardiovascular pharmacology.

• Jeopardy-style thought prompts used in class:

  • Where does a drug act in a signaling pathway: upstream versus downstream?

  • If a drug blocks the off-switch, what is the net effect on the signal?

  • What is the first messenger versus the second messenger in NO signaling?

  • What would be the effect of a PDE inhibitor on cGMP levels and PKG activity?

Practical and real-world connections

• Therapeutic use: nitrates relieve angina by dilating coronary arteries and veins, reducing myocardial oxygen demand and improving blood flow.

• Safety and administration: sublingual delivery provides rapid onset; need for careful dosing to avoid hypotension and reflex tachycardia.

• Historical insight: the nitroglycerin story illustrates how a hazardous compound can become a life-saving medication; Nobel’s legacy connects to the science of signaling.

• Clinical implications: understanding upstream/downstream relationships helps predict which drug targets will yield desired therapeutic effects and which will have off-target consequences.

Quick recap: key terms and equations (LaTeX)

• First messenger: NO (nitric oxide): $NO$

• Endothelial NOS: NOS in endothelial cells activated by $\uparrow [Ca^{2+}]$ and binding to $Ca^{2+}/\text{calmodulin}$; converts $\mathrm{L-Arginine} \rightarrow NO + \mathrm{L-Citrulline}$

• NO receptor/enzyme in smooth muscle: soluble guanylyl cyclase (sGC)

• Second messenger in smooth muscle: $\mathrm{cGMP}$

• PKG activation: $\text{PKG} \xrightarrow{\text{activation}} \text{phosphorylation of targets}$

• Downstream effect: decreased $[Ca^{2+}]_{SM}$ leading to vasodilation

• cGMP production reaction: $\mathrm{GTP} \rightarrow \mathrm{cGMP}$

• Off-switch: $\mathrm{cGMP} \xrightarrow{\text{PDE}} \mathrm{GMP}$

• NO travel distance: localized paracrine signaling (roughly 3–4 cells)

• Dose example: sublingual nitroglycerin dose around $0.6\ \text{mg}$

Summary takeaways

• Atherosclerosis progression involves LDL deposition, fatty streaks, inflammation, plaque formation, and potential thrombus formation leading to MI or stroke.

• Nitrates treat angina by exploiting NO signaling to dilate arteries and veins, reducing heart workload and improving oxygen delivery.

• NO acts as a short-lived first messenger that triggers a cascade culminating in cGMP production and PKG-mediated smooth muscle relaxation.

• Signaling pathways operate like dominoes; each step must function for the final physiological effect.

• Drug design can target upstream (NO production, Ca2+ signaling) or downstream (sGC, cGMP, PKG, PDE) components to achieve therapeutic goals or to modulate safety profiles.

• Understanding the balance of signaling and the existence of off-switches like PDEs is crucial to predict drug effects and avoid adverse outcomes.

Exam Questions

1. Which type of cell-cell signaling involves a cell activating itself by releasing a signaling molecule that binds its own receptor?
   a) Paracrine signaling
   b) Endocrine signaling
   c) Autocrine signaling
   d) Nervous signaling

2. Explain why chronic diseases, such as heart disease and cancer, are often favored by drug companies compared to acute infections, in the context of drug development and revenue.

3. Describe the initial steps of atherosclerosis, specifically focusing on the role of LDL cholesterol and the formation of fatty streaks in arterial walls.

4. A patient presents with angina (chest pain). What is the historical origin of nitroglycerin, and how is it typically administered for rapid relief of angina, including the typical dose range?

5. Outline the mechanistic cascade by which nitroglycerin causes vasodilation, starting with its conversion to nitric oxide (NO) and detailing its role as a first messenger.

6. Identify the two primary cell types involved in artery signaling architecture and explain their communication axis regarding NO-mediated vasodilation.

7. In the NO signaling pathway, what enzyme is activated in endothelial cells in response to calcium rise, and what is the key reaction it catalyzes?
   $\text{L-Arginine} \rightarrow \text{NO} + \text{L-Citrulline}$ (Fill in the blanks):
   Activated enzyme:
   Substrate:
   Products:

8. Once NO diffuses into smooth muscle cells, what enzyme does it activate, and what second messenger is produced as a result? Include the chemical reaction.

9. What is the role of Protein Kinase G (PKG) in the smooth muscle cell after it is activated by cGMP, and what is the ultimate effect on intracellular $Ca^{2+}$ levels and smooth muscle tone?

10. Describe the concept of an "off-switch" in signaling pathways. Specifically, detail two mechanisms by which NO signaling is terminated, including the role of phosphodiesterases (PDEs) in relation to cGMP.

11. A novel drug is developed that inhibits phosphodiesterase (PDE) activity in smooth muscle cells. Predict the effect of this drug on cGMP levels, PKG activity, and the overall vascular response, and explain your reasoning.

12. Using the domino analogy for signaling pathways, explain what would happen to the vasodilatory response if a drug were to block the activation of soluble guanylyl cyclase (sGC) in smooth muscle cells.